TGF beta 2 Proteins, Antibodies, cDNA Clones Research Reagents

TGFB2 (Transforming Growth Factor Beta 2) is a protein coding gene located on human chromosome 1q41. TGFB2 is also known as LDS4, G-TSF and TGF-beta2. The human TGFB2 gene encodes a 47748 Da protein containing 414 amino acids. The TGFB2 protein is broadly expressed in prostate, lung and other tissues. Among its related pathways are Cell adhesion_Plasmin signaling and Degradation of the extracellular matrix. TGFB2 is related to protein homodimerization activity and signaling receptor binding. TGFB3 is an important paralog of TGFB2 gene. TGFB2 is associated with some diseases, including Loeys-Dietz Syndrome 4 and Holt-Oram Syndrome.

TGF beta 2 Protein (4)

    TGF beta 2 Antibody (1)

      TGF beta 2 cDNA Clone (53)

      NM_003238.3
      NM_009367.3
      AF153013.1
      XM_001103911.2
      XM_853584.4

      In cloning vector

      TGF beta 2 Lysate (3)

        TGF beta 2 Background

        TGF beta 2 (Transforming growth factor beta 2), an extracellular glycosylated protein, which belongs to the TGF-beta family. TGF-beta regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. TGF beta 2 suppression is a promising therapeutic approach for malignant tumor therapy. The signaling pathway of TGF beta 2/Smad plays an important role in the pathological process in posterior capsule opacification (PCO) after cataract surgery. Silencing Smad2 and Smad3 efficiently blocked the effect of TGF beta 2 on cell proliferation, migration, and extracellular matrix production. TGF beta 2 activation of MEKK3/ERK1/2/5 signaling modulates Has2 expression and hyaluronan (HA) production leading to the induction of epithelial to mesenchymal transformation (EMT) events. Besides, the upregulation of the TGF beta 2 level is a common pathological feature of Alzheimer's disease (AD) brains and suggests that it may be closely linked to the development of neuronal death related to AD.

        TGF beta 2 References

        • Schlingensiepen KH, et al. (2006) Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev. 17(1-2): 129-39.
        • Ghatpande SK, et al. (2010) Transforming growth factor beta2 is negatively regulated by endogenous retinoic acid during early heart morphogenesis. Dev Growth Differ. 52(5): 433-55.
        • Noguchi A, et al. (2010) Transforming growth factor beta2 level is elevated in neurons of Alzheimer's disease brains. Int J Neurosci. 120(3): 168-75.
        • Li J, et al. (2011) Comparative effects of TGF-_2/Smad2 and TGF-_2/Smad3 signaling pathways on proliferation, migration, and extracellular matrix production in a human lens cell line. Exp Eye Res. 92(3): 173-9.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.